Plus Therapeutics Inc. Faces Nasdaq Deficiency Notice Over Delayed Quarterly Report Filing

Reuters
24 May
Plus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Faces Nasdaq Deficiency Notice Over Delayed Quarterly Report Filing

Plus Therapeutics, Inc. (Nasdaq: PSTV) has received a delinquency notification from Nasdaq due to a delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2025. The company was informed on May 21, 2025, about its non-compliance with Nasdaq Listing Rule 5250(c)(1), which mandates timely filing of periodic financial reports with the SEC. Plus Therapeutics must submit a compliance plan by July 21, 2025, and is working to promptly file the report and normalize its filing schedule for the rest of the year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-125860), on May 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10